Hyloris Pharmaceuticals SA (EBR:HYL)

Belgium flag Belgium · Delayed Price · Currency is EUR
5.90
-0.14 (-2.32%)
Mar 28, 2025, 5:21 PM CET
-46.61%
Market Cap 165.20M
Revenue (ttm) 10.04M
Net Income (ttm) -6.34M
Shares Out 28.00M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,071
Average Volume 18,550
Open 6.14
Previous Close 6.04
Day's Range 5.90 - 6.14
52-Week Range 2.89 - 12.75
Beta 0.33
RSI 50.76
Earnings Date Mar 20, 2025

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 49
Stock Exchange Euronext Brussels
Ticker Symbol HYL
Full Company Profile

Financial Performance

In 2024, Hyloris Pharmaceuticals's revenue was 10.04 million, an increase of 138.30% compared to the previous year's 4.21 million. Losses were -6.34 million, -58.76% less than in 2023.

Financial Statements

News

There is no news available yet.